Advanced Cancers Clinical Trial
Official title:
Phase I Trial of Cetuximab and Erlotinib (EGFR Inhibitors) and SIR-Spheres (Yttrium Microspheres) in Patients With Advanced Malignancies and Liver Metastases
The goal of this clinical research study is to find the highest tolerable dose of the
combination of selective internal radiation (SIR)-Spheres with yttrium-90 attached and
cetuximab. Some participants will also take erlotinib with this combination.
Yttrium-90 microspheres are designed to treat cancer that has spread to the liver.
SIR-Spheres are designed to deliver the radiation directly to the liver. This radiation may
cause the tumor cells to die.
Cetuximab and erlotinib are drugs that are designed to block the epidermal growth factor
receptor (EGFR). EGFR is a protein that helps cancer cells grow. Blocking the EGFR may stop
tumors from growing.
Study Groups:
If you are found to be eligible to take part in this study, your doctor will decide which
group you will be in based on your medical history.
- Group 1 will receive SIR-Spheres with yttrium-90 attached and cetuximab.
- Group 2 will receive SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib.
Once it is decided which combination you will receive, you will be assigned to a dose level
of cetuximab based on when you join the study. Up to 3 dose levels of cetuximab will be
tested. Three (3) to 6 participants will be enrolled at each dose level. The first group of
participants will receive the lowest dose level. Each new group will receive a higher dose
than the group before it, if no intolerable side effects were seen. This will continue until
the highest tolerable doses of the combinations are found.
All study participants will receive a dose level of the SIR-Spheres with yttrium-90 attached
based on the results of the "break-through" scan (described below).
If you are assigned to Group 2, you will also receive erlotinib. If you are tolerating
erlotinib well after 1 cycle, you may begin receiving a higher dose of erlotinib in Cycle 3
and beyond.
Break-through Scan:
You will have a "break-through" scan within 29 days before receiving the SIR-Spheres with
yttrium-90 microspheres. This scan will measure the supply of blood in your lungs and will
also be used to check your liver. For this test, a small amount of radioactive material will
be injected into your liver and images will be taken to see how the material moves through
your lungs and liver. The radioactive material will be given through a catheter in a vein in
your groin. A catheter is a sterile, flexible tube that will be placed through your groin
artery into the artery leading to your liver while you are under local anesthesia. Your
doctor will explain this procedure to you in more detail.
The results of this test will be used to determine if you will receive a full or partial
dose of SIR-Spheres with yttrium-90 microspheres.
Radiation and Study Drug Administration:
Each study cycle is 28 days.
You will receive the SIR-Spheres with yttrium-90 microspheres on Day 1 of Cycle 1 only.
Before you receive the SIR-Spheres with Yttrium-90 microspheres, you will receive sedative
drugs by vein to put you to sleep. SIR-Spheres with yttrium-90 microspheres will then be
given to you through a catheter in a vein in your groin.
After you are given the yttrium-90 microspheres, the catheter will be removed and pressure
will be applied to your groin to stop any bleeding. You will then be monitored for 6 hours
to check for any side effects. If needed, you will be given pain medication after the
infusion. Your study doctor will decide which pain medications to give you.
Cetuximab will be given by vein 1 time each week during Weeks 2-4 of Cycle 1, and then 1
time every week for Cycles 2 and beyond. The first time you receive cetuximab, it will be
given over 2 hours. Every time you receive cetuximab after that, it will be given over 1
hour.
If you are assigned to receive erlotinib, you will take it by mouth 1 time each day starting
on Day 1 of Cycle 2. You should take it at the same time each day . You should take it on an
empty stomach either 1 hour before or 2 hours after eating. The study staff will give you
more instructions for taking erlotinib.
Study Visits:
On Day 1 of Cycle 1:
- Before you receive the SIR-Spheres with yttrium-90 microspheres, your blood vessels
will be checked. For this test, you will receive an x-ray dye through the catheter that
will help the study staff look at the arteries leading to your liver and surrounding
areas.
- You will have a physical exam and your medical history will be recorded.
- Blood (about 2 teaspoons) will be drawn for routine tests.
During Weeks 2 and 4 of Cycle 1:
- You will have a physical exam and your medical history will be recorded.
- Blood (about 2 teaspoons) will be drawn for routine tests.
Every 8 weeks, you will have an x-ray, CT scan, MRI scan, and/or PET/CT scan to check the
status of the disease.
About every 4 weeks starting at the beginning of Cycle 2:
- You will have a physical exam and your medical history will be recorded
- Blood (about 2 teaspoons) will be drawn for routine tests. This routine blood draw will
include a pregnancy test if you are able to become pregnant.
Length of Study:
You receive the study drugs for as long as you are benefitting. You will no longer be able
to take the study drug if the disease gets worse, if intolerable side effects occur, or if
you are unable to follow study directions.
This is an investigational study. SIR-Spheres are FDA-approved and commercially available to
treat metastatic colorectal cancer that has spread to the liver. Yttrium-90 microspheres are
FDA-approved for hepatic arterial therapy and the treatment of liver metastases. Cetuximab
is FDA-approved and commercially available to treat head and neck and colorectal cancer.
Erlotinib is FDA-approved and commercially available to treat non-small cell lung cancer
(NSCLC) and pancreatic cancer. The use of this combination to treat advanced cancer is
investigational.
Up to 136 patients will take part in this study. All will be enrolled at MD Anderson.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01213238 -
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
|
Phase 1 | |
Recruiting |
NCT02160366 -
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
|
||
Completed |
NCT00903708 -
LY2275796 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00379353 -
The Effects of Thalidomide on Symptom Clusters
|
Phase 2 | |
Terminated |
NCT00499382 -
Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging
|
N/A | |
Completed |
NCT02459964 -
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
|
Phase 4 | |
Completed |
NCT01430572 -
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
|
Phase 1 | |
Completed |
NCT02561234 -
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01375114 -
The Effects of Ginseng on Cancer-Related Fatigue
|
Phase 2 | |
Completed |
NCT01201694 -
Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)
|
Phase 1 | |
Completed |
NCT01454804 -
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT02801045 -
Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient
|
N/A | |
Completed |
NCT02873975 -
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
|
Phase 2 | |
Completed |
NCT01983969 -
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT02272595 -
Rational Therapeutics Based on Matched Tumor and Normal Tissue
|
||
Active, not recruiting |
NCT01999491 -
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
|
Phase 1 | |
Recruiting |
NCT03375983 -
Plasmodium Immunotherapy for Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT02571036 -
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
|
Phase 1 | |
Withdrawn |
NCT01608139 -
Study of Curcumin, Vorinostat, and Sorafenib
|
Phase 1 | |
Completed |
NCT01024166 -
Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study
|
N/A |